PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Auer, F.* ; Morcos, M.N.F.* ; Sipola, M.* ; Akhtar, I.* ; Moisio, S.* ; Vogt, J.* ; Haag, R.* ; Lahnalampi, M.* ; Tuononen, T.J.* ; Hanel, A.* ; Viitasalo, A.* ; Friedrich, U.A. ; Dahl, A.* ; Prexler, C.* ; Pandyra, A.A.* ; Stepensky, P.* ; Takagi, M.* ; Borkhardt, A.* ; Heinäniemi, M.* ; Hauer, J.*

Trajectories from single-cells to PAX5-driven leukemia reveal PAX5-MYC interplay in vivo.

Leukemia, DOI: 10.1038/s41375-025-02626-2 (2025)
Verlagsversion Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
PAX5 acts as a master regulator of B-cell proliferation and differentiation. Its germline and somatic deregulation have both been implicated in the development of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, the process how reduced PAX5 transcriptional activity mediates progression to BCP-ALL, is still poorly understood. Here, we characterized the longitudinal effects of PAX5 reduction on healthy, pre-leukemic and BCP-ALL cells at the single-cell level. Cell-surface marker analysis revealed a genotype-driven enrichment of the pre-BII population in healthy Pax5± mice. This population showed downregulated B-cell receptor signaling, while DNA replication/repair and cell-cycle signaling pathways were upregulated. Moreover, we observed a shift in the kappa/lambda light chain ratio toward lambda rearranged B-cells. Transplantation experiments further validated a delay of Pax5± pre-BII cells in maturation and transition to IgM-positivity. Additionally, single-cell RNA-Sequencing and bulk ATAC-Sequencing of different stages of BCP-ALL evolution showed that Pax5± pre-leukemic cells lose their B-cell identity and display Myc activation. Subsequently, BCP-ALLs acquired additional RAG-mediated aberrations and driver mutations in JAK-STAT and RAS-signaling pathways. Together, this study elucidates molecular and functional checkpoints in PAX5-mediated pre-leukemic cell progression exploitable for therapeutic intervention and demonstrates that PAX5 reduction is sufficient to initiate clonal evolution to BCP-ALL through activation of MYC.
Impact Factor
Scopus SNIP
Altmetric
13.400
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Acute Lymphoblastic-leukemia; Surrogate Light-chain; Gene-expression; Target Genes; B-cells; Pro-b; Transcription; Recombination; Chromatin; Susceptibility
Sprache englisch
Veröffentlichungsjahr 2025
HGF-Berichtsjahr 2025
ISSN (print) / ISBN 0887-6924
e-ISSN 1476-5551
Zeitschrift Leukemia
Verlag Nature Publishing Group
Verlagsort Campus, 4 Crinan St, London, N1 9xw, England
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Pancreatic Islet Research (IPI)
POF Topic(s) 90000 - German Center for Diabetes Research
PSP-Element(e) A-502600-001
Förderungen Bioinformatics center at the University of Eastern Finland
EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council)
DOI 10.1038/s41375-025-02626-2
WOS ID 001491307500001
Scopus ID 105005538970
PubMed ID 40394211
Erfassungsdatum 2025-05-21
[➜Korrektur melden]